Elsevier, together with Boehringer Ingelheim, Eli Lilly and Company, Pierre Fabre, Sanofi, Servier and others, has further extended its drug-drug interaction risk calculator (DDIRC) within PharmaPendium. The DDIRC 2.0 aims to help scientists improve patient safety and effectively manage drug-drug interaction (DDI) risks across the drug development process.
The tool enables researchers to track predictions through the development cycle from pre-clinical to phase III trials and project manage multiple simulations at the same time. It also assists with inclusion and exclusion criteria for patients in phase II and III trials.
